Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab (Q87359857)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Giuseppina Campisi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Vittorio Fusco

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

26 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

Supportive Care in Cancer

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1737-1738

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

8 March 2020

cites work

1 reference

12 December 2020

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

1 reference

12 December 2020

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

1 reference

12 December 2020

Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients

1 reference

12 December 2020

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

12 December 2020

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

1 reference

12 December 2020

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

12 December 2020

Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?

1 reference

12 December 2020

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

1 reference

12 December 2020

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

12 December 2020

10.1007/S00520-014-2159-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570104%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference